GlaxoSmithKline’s Eperzan (albiglutide) for the treatment of type 2 diabetes has been authorized in Europe. The drug employs Novozymes Biopharma’s albumin-based VELTIS half-life extension technology, which enables once per week administration of the drug.   Novozymes’ VELTIS technology represents a series of engineered human albumins that in combination with a drug candidate, offers the potential for control of the therapeutic half-life, which allows for reducing the dosing frequency of dr...